The Na ϩ /dicarboxylate cotransporter NaDC1 absorbs citric acid cycle intermediates from the lumen of the small intestine and kidney proximal tubule. No effective inhibitor has been identified yet, although previous studies showed that the nonsteroidal anti-inflammatory drug, flufenamate, inhibits the human (h) NaDC1 with an IC 50 value of 2 mM. In the present study, we have tested compounds related in structure to flufenamate, all anthranilic acid derivatives, as potential inhibitors of hNaDC1. We found that N-(p-amylcinnamoyl)anthranilic acid (ACA) and 2-(p-amylcinnamoyl)amino-4-chloro benzoic acid (ONO-RS-082) are the most potent inhibitors with IC 50 values lower than 15 M, followed by N-(9-fluorenylmethoxycarbonyl)-anthranilic acid (Fmoc-anthranilic acid) with an IC 50 value of ϳ80 M. The effects of ACA on NaDC1 are not mediated through a change in transporter protein abundance on the plasma membrane and seem to be independent of its effect on phospholipase A 2 activity. ACA acts as a slow inhibitor of NaDC1, with slow onset and slow reversibility. Both uptake activity and efflux are inhibited by ACA. Other Na ϩ /dicarboxylate transporters from the SLC13 family, including hNaDC3 and rbNaDC1, were also inhibited by ACA, ONO-RS-082, and Fmoc-anthranilic acid, whereas the Na ϩ /citrate transporter (hNaCT) is much less sensitive to these compounds. The endogenous sodium-dependent succinate transport in Caco-2 cells is also inhibited by ACA. In conclusion, ACA and ONO-RS-082 represent promising lead compounds for the development of specific inhibitors of the Na ϩ /dicarboxylate cotransporters.
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The metabolic intermediates of the citric acid cycle, including succinate, citrate, and ␣-ketoglutarate, are transported across the plasma membranes of epithelial cells by the Na ϩ / dicarboxylate cotransporters from the SLC13 family (Pajor, 2006) . SLC13 family members include the low-affinity dicarboxylate transporter, NaDC1, the high-affinity Na ϩ /dicarboxylate cotransporter, NaDC3, and the Na ϩ /citrate transporter, NaCT. NaDC1 is found on the apical membranes of renal proximal tubule and small intestinal cells. In the kidney, NaDC1 helps to regulate the concentration of citrate in the urine, which is an important determinant in the development of kidney stones; ϳ50% of patients with kidney stones have hypocitraturia (Pak, 1991) . NaDC1 also participates in organic anion secretion in the kidney by providing dicarboxylate substrates, particularly ␣-ketoglutarate, to the organic anion transporter of the basolateral membrane (Dantzler and Evans, 1996) . NaDC1 may play an indirect role in regulating blood pressure; succinate and ␣-ketoglutarate activate specific G-protein-coupled receptors in the renal proximal tubule (He et al., 2004) . Finally, mutations in NaDC1 homologs found in the digestive tract of Drosophila melanogaster and Caenorhabditis elegans lead to an extension of lifespan (Rogina et al., 2000; Fei et al., 2004) , suggesting a possible role for NaDC1 in metabolic control or aging.
To date, no high-affinity inhibitors have been identified for any member of the SLC13 family. Our previous studies identified the nonsteroidal anti-inflammatory drug flufenamate as an inhibitor of hNaDC1. The IC 50 value was 2 mM using succinate as a substrate and 0.5 mM using methylsuccinate (Pajor and Sun, 1996; Smith et al., 2003) . A high-affinity inhibitor would be very useful for in vitro studies of NaDC1 to quantitate the transporter in the membrane and to characterize mutant transporters with alterations in substrate translocation but not binding. An effective and selective inhibitor could help to identify physiological roles of NaDC1. Furthermore, an inhibitor may lead to a potential drug if inhibition of NaDC1 activity in humans is linked to aging or metabolism.
In the present study, we tested anthranilic acid derivatives related in structure to flufenamate as potential inhibitors of hNaDC1. We found that N-(p-amylcinnamoyl)anthranilic acid (ACA) and 2-(p-amylcinnamoyl)amino-4-chloro benzoic acid (ONO-RS-082) are the most potent inhibitors with IC 50 values lower than 15 M, followed by N-(9-fluorenylmethoxycarbonyl)-anthranilic acid (Fmoc-anthranilic acid) with an IC 50 value of ϳ80 M. The effects of ACA on hNaDC1 are not mediated through a change in transporter protein abundance on the plasma membrane and seem to be independent of its effect on phospholipase A 2 (PLA 2 ) activity. ACA acts as a slow inhibitor of NaDC1, with slow onset and slow reversibility. Both transport uptake and efflux are inhibited by ACA. Other Na ϩ /dicarboxylate transporters from the SLC13 family, including hNaDC3 and rbNaDC1, were also inhibited by ACA, ONO-RS-082, and Fmoc-anthranilic acid, whereas the Na ϩ /citrate transporter hNaCT is much less sensitive to these compounds. The endogenous sodium-dependent succinate transport activity in the human colon carcinoma cell line, Caco-2, is also sensitive to inhibition by ACA. In conclusion, ACA and ONO-RS-082 are promising lead compounds for the development of specific inhibitors of the Na ϩ /dicarboxylate cotransporters.
Materials and Methods
Chemicals. The structures of the compounds used in this study are shown in Fig. 1 , and the names are listed in Table 1 . ACA, ONO-RS-082, and Tranilast were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA), and all other chemicals were from Sigma-Aldrich (St. Louis, MO).
Cell Culture. The CUBS cell line consisting of HRPE cells (derived from human retinal pigment epithelium) stably transfected with the human NaDC1 cDNA (Smith et al., 2003) was a generous gift from Dr. Chari Smith (GlaxoSmithKline, Research Triangle Park, NC). Control cells were nontransfected HRPE cells. Cells were cultured in modified Eagle's medium containing Earle's salts, GlutaMAX I, and 25 mM HEPES (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT), 100 U/ml penicillin, 100 g/ml streptomycin, and 700 g/ml G-418 (Geneticin; Invitrogen) at 37°C in 5% CO 2 . For uptake experiments, cells were plated on white-sided 24-well plastic Visiplates (PerkinElmer Life and Analytical Sciences, Waltham, MA) at a density of 2.5 ϫ 10 5 cells/well (24-well plate) in the same medium with 2.5 mM butyrate added. Control HRPE cells were plated at the same density but without G418 or butyrate in the medium. Uptake assays were done in confluent monolayers approximately 36 h after plating.
For transient transfections with hNaDC3 and hNaCT, HRPE cells were plated at 1.2 ϫ 10 5 cells/well, and each well of cells was transfected with 1.8 l of FuGENE 6 (Roche, Indianapolis, IN) and 0.6 g of plasmid DNA (9:3 ratio) (Pajor and Randolph, 2005) . Transport assays were done 48 h after transfections.
Succinate Uptake Assay. Transport assays at room temperature were as described previously (Pajor and Randolph, 2005) . The sodium buffer contained 120 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 1.2 mM CaCl 2 , 5 mM D-glucose, and 25 mM HEPES, with pH adjusted to 7.4 with 1 M Tris. Choline buffer contained 120 mM choline chloride in place of NaCl. For the assays, each well was washed twice with 1 ml of sodium buffer and then preincubated with inhibitor in sodium buffer for 15 min, followed by two washes with 1 ml each of Fig. 1 . Structures of the compounds used in this study. The names of the compounds are listed in Table 1 .
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at ASPET Journals on April 7, 2017 molpharm.aspetjournals.org sodium buffer. Inhibitors were prepared fresh each day as dimethyl sulfoxide stocks, with a final volume of dimethyl sulfoxide of less than 1%. Cells were preincubated with inhibitors 15 min (unless otherwise specified in the figure legends). Transport solution (0.25 ml/well) consisting of [ 14 C]succinate (10 or 100 M final concentration) in sodium buffer, with or without added inhibitor, was then added to the cells. After 30 min, the uptake measurements were stopped, and radioactivity was removed with four 1-ml washes of choline buffer. After the last wash was removed, each well of cells was dissolved in 0.5 ml of scintillation cocktail, OptiPhase Supermix (PerkinElmer Life and Analytical Sciences). The plates were sealed with plastic plate covers and were counted directly in a Microbeta Trilux 1450 plate scintillation counter (PerkinElmer Life and Analytical Sciences). For experiments involving CUBS cells, background corrections were made based on uptake activities in control HRPE cells. For experiments involving transfected cells, uptake activities in vector-transfected cells were subtracted from activities in NaDC plasmid-transfected cells. There was no difference in the background counts obtained with vector-transfected or nontransfected cells (results not shown).
For the calculation of K i values from Dixon plots, inhibition of transport activity was measured at multiple inhibitor and substrate concentrations. The data were analyzed by linear regression, and the x-axis value corresponding to the intersection of the lines was taken as ϪK i (Segel, 1975) . To determine IC 50 values (the inhibitor concentration resulting in 50% inhibition), the transport of 10 M [
14 C]succinate was measured in the presence of increasing concentrations of inhibitor, and the resulting activity (v%, as a percentage of control) was analyzed by nonlinear regression using v% ϭ IC 50 /([I] ϩ IC 50 ) ϫ 100, where [I] represents the inhibitor concentration. Statistical analysis with one-way analysis of variance or Student's t test was done using the SigmaStat program (Systat Software, Inc., Point Richmond, CA). Each experimental point was the mean of four replicate wells, and each experiment was repeated at least two or three times (different plating or transfection experiments).
Efflux Assays. Efflux assays in CUBS cells (Smith et al., 2003) were done using the nonmetabolizable substrate, [
3 H]methylsuccinate (a gift of Dr. Chari Smith, GlaxoSmithKline). In preliminary experiments (data not shown), we found that the cells required at least 30 min of incubation with substrate for preloading, after which the intracellular radioactivity reached a plateau. Therefore, the cells were preloaded by incubating with 10 or 100 M [ 3 H]methylsuccinate in Na ϩ buffer for 30 min. The cells were then washed four times with choline buffer to remove extracellular radioactivity, followed by incubation in sodium buffer for 1 min to allow efflux of radiolabeled substrate. To stop the efflux, each well was washed four times with choline buffer, and 1% SDS was added to solubilize the cells. The samples were transferred to scintillation vials (because the plate counter does not measure 3 H accurately), combined with scintillation cocktail, and counted on a Packard Tri-Carb 2100TR scintillation counter (PerkinElmer Life and Analytical Sciences).
Caco-2 Cells. The Caco-2 cell line (human colon adenocarcinoma) was obtained from the American Type Culture Collection (Manassas, VA). The cells were cultured in DMEM with 4.5 g/l glucose (Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (Hyclone), 100 U/ml penicillin G, 100 g/ml streptomycin, 1% (v/v) sodium pyruvate, and 1% (v/v) nonessential amino acids (Sigma). Cells were seeded in 24-well collagen-coated plates, maintained with medium changes every other day, and then used for transport assays 21 days after reaching confluence. Sodium-dependent transport activity was the difference between transport measured in sodium and choline-containing buffers.
Cell Surface Biotinylation. Cell surface biotinylations of NaDC1 were done using a membrane-impermeant reagent, sulfosuccinimidyl-6-(biotinamido) hexanoate (Sulfo-NHS-LC-Biotin; Pierce, Rockford, IL), as described previously (Pajor and Randolph, 2005) . Biotinylated proteins were separated by SDS-polyacrylamide gel electrophoresis in 7.5% acrylamide, and NaDC1 was identified using antibodies (1:1000 dilution).
Results

Initial Inhibitor Screen. The time course of [
14 C]succinate uptake into the CUBS cell line (stably transfected HRPE cells expressing hNaDC1) is linear through 45 min (Fig. 2) . Therefore, 30-min uptake activities were used in subsequent experiments as estimates of initial rates. Succinate uptake activity in control nontransfected HRPE cells was very low (Fig. 2) . The transport of succinate in choline buffer in the CUBS cell line was the same as in nontransfected HRPE cells (results not shown).
Several commercially available anthranilic acid derivatives were tested as potential inhibitors of NaDC1 (Fig. 3) . CUBS cells expressing hNaDC1 were incubated with test inhibitors, each at 100 M concentration, and the effect on succinate transport was measured. We found that ACA (compound 1) and the related compound ONO-RS-082 (compound 2) produced greater than 80% inhibition of succinate transport. Incubation with N-Fmoc-anthranilic acid (compound 4) resulted in approximately 45% inhibition. None of the other compounds produced significant inhibition at 100 M concentration. There was also no inhibition of succinate transport by anthranilic acid, the parent compound (data not shown). The lack of inhibition by 100 M flufenamate was consistent with the apparent IC 50 value of 2 mM in hNaDC1 expressed in Xenopus laevis oocytes (Pajor and Sun, 1996) .
Kinetics of Inhibition. The mechanism of inhibition of NaDC1 by ACA was examined using Dixon plots (Fig. 4) . The lines intersected at the x-axis, suggesting that the mechanism of inhibition is noncompetitive (Segel, 1975) . In the experiment shown in Fig. 4 , the K i value was 12.5 M, and in four experiments, the K i value was 15.3 Ϯ 3.3 M (mean Ϯ S.E.M.). We also compared the IC 50 values for the three inhibitory compounds, ACA, ONO-RS-082, and Fmoc-anthranilic acid, measured at a single substrate concentration (10 M succinate). The IC 50 values were 10.6 Ϯ 2.4 (ACA), 9.2 Ϯ 0.3 (ONO-RS-082), and 85.3 Ϯ 13.3 M (Fmoc-anthranilic acid), n ϭ 3 (results not shown). Cell Surface Biotinylation. One possible explanation for the decrease in transport activity after ACA treatment is a decrease in the amount of transporter protein at the plasma membrane. This was tested by cell surface biotinylation using the membrane-impermeant reagent Sulfo-NHS-LC-Biotin. Cells treated with ACA did not show any evidence of internalization of hNaDC1 protein compared with controls incubated with buffer for the same incubation period (Fig. 5) . Therefore, the decreased activity seen after incubation with ACA is not due to internalization of the transporter.
Time Courses of ACA Inhibition. Several alternative explanations could account for the apparent noncompetitive inhibition of hNaDC1 by ACA. For example, ACA could act as an irreversible inhibitor or a slow, reversible inhibitor, both of which would produce apparent noncompetitive inhibition (Segel, 1975; Morrison, 1982) . In time course experiments, the inhibition by ACA did not occur immediately, and the inhibition was not evident until after 2 min of incubation (Fig. 6) . A longer time course (Fig. 7A) shows that the inhibition by ACA requires at least 15 to 30 min of preincubation. The inhibition also seemed to be reversible, although very slow. In 1 h, the activity of hNaDC1 recovered by approximately 20% (Fig. 7B) . The inhibition by ACA was not dependent on cations, because the extent of inhibition was the same in sodium or choline buffer. Transport activity remaining after pretreatment with 30 M ACA was 66 Ϯ 5% in sodium buffer compared with 71 Ϯ 3.5% in choline buffer (n ϭ 3 experiments).
Efflux Experiments. We next tested the efflux of the nonmetabolizable substrate [ 3 H]methylsuccinate in the CUBS cell line. The cells were preloaded with radiolabeled substrate in sodium buffer for 30 min. The extracellular radioactivity was washed away, and the efflux was measured for 1 min in sodium buffer with or without 100 M ACA. As shown in Fig. 8 , ap- Table 1 and Fig. 1 . The test inhibitor concentration was 100 M. Thirty-minute uptake measurements were done, and the data are expressed as a percentage of control in the absence of inhibitor. The data points represent mean Ϯ range or S.E.M., n ϭ 2 to 3 experiments. ‫,ء‬ significant difference from control, p Ͻ 0.05. (Fig. 8) , indicating that efflux and influx are inhibited by ACA.
Phospholipase A 2 Inhibitors. Because ACA is known to be a nonspecific inhibitor of PLA 2 (Konrad et al., 1992) , we wanted to rule out the possibility that the effects of ACA on NaDC1 are mediated indirectly by inhibition of PLA 2 . Two other inhibitors of PLA 2 , structurally unrelated to ACA, were tested, but they did not inhibit succinate transport by hNaDC1 (Fig. 9) . p-Bromophenacyl bromide (BPB) inhibits secreted PLA 2 by binding covalently to a histidine residue (Mayer and Marshall, 1993) . A previous study showed that BPB at 5 or 10 M inhibits PLA 2 activity in cultured cells without producing toxicity (Liu and Levy, 1997) . AACOCF 3 (arachidonyl trifluoromethyl ketone) is a slow-onset inhibitor of the calcium-dependent cytosolic PLA 2 (Street et al., 1993 ). Both compounds were tested after 15 min of preincubation. The results suggest that the effects of ACA on hNaDC1 are distinct from its inhibition of PLA 2 .
Species and Isoform Differences in Specificity. We also examined the effects of the test inhibitors on transport activity of other SLC13 members, the high-affinity Na ϩ /dicarboxylate cotransporter hNaDC3 (Wang et al., 2000) , the Na ϩ /citrate cotransporter hNaCT (Inoue et al., 2002) , and the rabbit (rb) NaDC1 (Pajor and Sun, 1996) . The activity of hNaCT was tested using citrate as a substrate, whereas the substrate for hNaDC3 and rbNaDC1 was succinate. As shown in Fig. 10 , the three transporters were sensitive to inhibition by some of the anthranilic acid derivatives. All three transporters were very sensitive to inhibition by ACA (compound 1), but in general, hNaCT was less sensitive to ONO-RS-082 (compound 2) and Fmoc-anthranilic acid (compound 4) compared with the other transporters. The rbNaDC1 was inhibited by flufenamate by ϳ40% (compound 10), whereas hNaDC3 and hNaCT were not affected by flufenamate. There was no inhibition of the three transporters by the other compounds (compound 11 shown in Fig. 10 , other compounds not shown).
Inhibition of Endogenous Transporter. The human colon carcinoma cell line, Caco-2, is often used as a model of the small intestine. This cell line expresses sodium-dependent transport of succinate that is predominantly mediated by NaDC1 with some contribution by NaCT (Weerachayaphorn and . As shown in Fig. 11 , the endogenous succinate transport activity in Caco-2 cells was inhibited more than 50% by treatment with ACA. Therefore, ACA inhibits both transfected recombinant NaDC1 and the endogenous NaDC1 found in Caco-2 cells.
Discussion
The main finding of this study is that anthranilic acid derivatives, including ACA, ONO-RS-082, and Fmoc-anthranilic acid, are inhibitors of the Na ϩ /dicarboxylate cotransporters from the SLC13 family. ACA and ONO-RS-082 inhibit transport with IC 50 values less than 15 M and thus represent the highest-affinity inhibitors of hNaDC1 to date. The effects of ACA are not mediated through internalization of the transporter and seem to be distinct from the effects of ACA on phospholipase A 2 . The preferred structure for inhibition of hNaDC1 seems to require a lipophilic moiety attached to the anthranilic acid moiety of the compound, because Fmoc-anthranilic acid (compound 4) was a more effective inhibitor compared with Tranilast (compound 3) or the compounds with smaller or more polar substituents. 
Downloaded from
Flufenamate was identified in previous studies as a lowaffinity inhibitor of both low-affinity (NaDC1) and high-affinity (NaDC3) Na ϩ /dicarboxylate cotransporters. There are species differences in sensitivity to flufenamate, with rbNaDC1 being most sensitive, having an IC 50 value of 250 M (Pajor and Sun, 1996) , followed by flounder NaDC3, with an IC 50 value of ϳ1 mM (Burckhardt et al., 2004) , and hNaDC1, with an IC 50 value of 2 mM (Pajor and Sun, 1996) . All of the experiments were done using X. laevis oocytes as an expression system, and the cells were not preincubated with inhibitor. In the present study, the IC 50 value for flufenamate in rbNaDC1 was ϳ100 M, and the cells were preincubated with inhibitor before the assay, which may account for the apparent difference in affinity. Inhibition of the flounder NaDC3 by flufenamate seems to be mediated, at least in part, by an increased K ϩ conductance that is associated with the transporter, because it was not seen in control oocytes (Burckhardt et al., 2004) . It is possible that flufenamate activates a channel activity of the fNaDC3 protein, and several members of the SLC13 family have both channel and transport activity (Oshiro and Pajor, 2005) .
The onset of inhibition of hNaDC1 by ACA was not evident until after at least 2-min incubation time, consistent with the properties of a slow-binding inhibitor. This is the first report that ACA behaves as a slow-binding inhibitor. Slow-binding inhibitors are reversible, competitive inhibitors, but the rate of reaching equilibrium is slow relative to a classic inhibitor (Morrison, 1982) . Slow inhibition may occur if the formation of the enzyme-inhibitor complex occurs more slowly than the production of reaction product (in the case of a transporter, the "product" of the reaction is the appearance of substrate on the inside of the cell). Alternatively, the enzyme and inhibitor 10 . Sensitivity of the high-affinity Na ϩ /dicarboxylate cotransporter, hNaDC3, the Na ϩ /citrate cotransporter, hNaCT, and the low-affinity Na ϩ /dicarboxylate cotransporter, rbNaDC1 to inhibition by anthranilic acid derivatives. Compound names are listed in Table 1 , and structures are shown in Fig. 1 . HRPE cells were transiently transfected with plasmids containing transporter cDNA, control cells were transfected with the pcDNA3.1 vector plasmid. Transport of 10 M [ 14 C]succinate (hNaDC3, rbNaDC1) or [ 14 C]citrate (hNaCT) was measured for 30 min in the presence or absence of 100 M inhibitor. Data shown are means Ϯ range or S.E.M., n ϭ 2 to 3 experiments, except for rbNaDC1 with compound 11 (n ϭ 1). 
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complex forms quickly, but there is a slow isomerization step to an inactive complex. Slow inhibitors tend to be useful drugs because of their slow reversibility and the gradual accumulation of the inactive enzyme-inhibitor complex. Examples of drugs that are slow inhibitors include nonsteroidal anti-inflammatory drugs, such as indomethacin, that inhibit prostaglandin H synthase I by slow, reversible isomerization to a second enzyme-inhibitor complex (Callan et al., 1996) . The arachidonic acid analog AACOCF 3 is a slow and tight-binding inhibitor of the cytosolic phospholipase A 2 (Street et al., 1993) .
Our current working hypothesis for the effects of the inhibitors identified in the present study is that they act directly on hNaDC1 to inhibit transport. Other hypotheses could also explain the results, but they can be ruled out. For example, ACA could inhibit transport by affecting protein targeting. Both ACA (IC 50 ϭ 8 M) and ONO-RS-082 (IC 50 ϭ 6 M) have been shown to disrupt Golgi trafficking (de Figueiredo et al., 1999) . However, the cell surface abundance of hNaDC1 was not affected by incubation with ACA. A second possible explanation is that ACA inhibits transport indirectly by affecting the membrane potential or Na ϩ chemical gradient, which would affect hNaDC1 because it is electrogenic (Yao and Pajor, 2000) . ONO-RS-082 has been shown to inhibit the H ϩ /K ϩ -ATPase in stomach with an IC 50 value of 3.5 M, and the same study also reported that ONO-RS-082 has a protonophore effect (Sugita et al., 2005) . ACA is known to directly inhibit transient receptor potential cation channels with an IC 50 value of less than 4 M (Kraft et al., 2006) . However, changes in membrane potential or cation concentrations would not explain the time delay in the inhibition of hNaDC1 by ACA or the different sensitivities of NaDC1 homologs, all of which are electrogenic.
The hypothesis that ACA inhibition is mediated indirectly through its inhibition of PLA 2 is less likely than a direct effect of ACA on hNaDC1. There was no inhibition of hNaDC1 activity by two structurally unrelated PLA 2 inhibitors, BPB and AACOCF 3 . A compound that has not been reported to have PLA 2 inhibitory activity, Fmoc-anthranilic acid (compound 4), also inhibited transport with an IC 50 value of approximately 80 M. Although flufenamate has been shown to inhibit PLA 2 (Franson et al., 1980) , only the rabbit and not the human NaDC1 was inhibited by flufenamate. Furthermore, meclofenamate (compound 11) is also a PLA 2 inhibitor with an IC 50 value of ϳ1 M at 1 mM Ca 2ϩ (Franson et al., 1980 ), yet it had no effect on any of the transporters in this study.
In conclusion, we have identified several inhibitors of the Na ϩ /dicarboxylate cotransporters with micromolar affinities that represent the highest-affinity inhibitors of the SLC13 family to date. The most potent inhibitors of hNaDC1 were ACA, ONO-RS-082, and Fmoc-anthranilic acid. There were some differences in sensitivity to inhibition by anthranilic acid derivatives among the NaDC1 homologs tested (hNaDC3, rbNaDC1, and hNaCT), although the selectivity of the compounds was relatively low. The endogenous sodium-dependent succinate transport activity in the human colon carcinoma cell line, Caco-2, is also sensitive to inhibition by ACA. The kinetics of ACA inhibition of hNaDC1 were consistent with slow inhibition, and both uptake and efflux were affected. Our data indicate that ACA inhibits the activity of hNaDC1 independently of PLA 2 inhibition. However, the lack of specificity of ACA and ONO-RS-082 with NaDC orthologs and the effects on other targets including PLA 2 , transient receptor potential cation channels (Kraft et al., 2006) , and the stomach H ϩ /K ϩ -ATPase (Sugita et al., 2005) would limit the use of these compounds as NaDC1 inhibitors. Therefore, the structures of the anthranilic acid derivatives will serve as a starting point in drug design targeting hNaDC1.
